|
|
|
|
|
|||||||
|
Session 26
Oral Abstract Session
Pediatric/Maternal-Fetal HIV Infection and Issues in HIV-Infected Women Wednesday, 10 am - 12:30 pm 606-609 |
| Moderators |
Ram Yogev, Children’s Mem. Hosp., Chicago, IL and Susan Cohn, Univ. of
Rochester, NY and Jane Hitti, Univ. of Washington, Seattle | ||
| 10:00 111. | Combination Antiretroviral Therapy Corrects the Disruptions in the TCR V Z. C. Kou*, J. S. Puhr, M. Goodenow, and J. Sleasman Univ. of Florida, Gainesville
| ||
| 10:15 112. | Characterization of HIV-1 Specific Cellular Immune Responses in Stably Suppressed or Viremic Pediatric Patients E. Papasavvas*1, R. Rutstein2, E. C. Moore1, B. Thiel1, M. Pistilli1, A. Mackiewicz1, K. A. Jordan3, J. K. Sandberg3, G. M. Ortiz3, D. F. Nixon3, and L. J. Montaner1 1Wistar Inst., Philadelphia, PA; 2 Children's Hosp. of Philadelphia, PA; and 3Gladstone Inst. of Virology, San Francisco, CA
| ||
| 10:30 113. | Lactic Acidemia in Infants Exposed to Perinatal Antiretroviral Therapy A. Alimenti*, G. Ogilvie, D. Burdge, D. Money,, and J. Forbes Univ. of British Columbia, Children's and Women's Hlth. Ctr. of British Columbia, Vancouver, Canada
| ||
| 10:45 114. | Mother-to-Child HIV Transmission Rates According to Antiretroviral Therapy, Mode of Delivery, and Viral Load (PACTG 367) D. Shapiro*1, R. Tuomala2, R. Samelson3, S. Burchett4, G. Ciupak5, J. McNamara6, H. Pollack7, and J. Read8 1Harvard Sch. Publ. Hlth., Boston, MA; 2Brigham & Women's Hosp., Boston, MA; 3Albany Med. Ctr., NY; 4Children's Hosp., Harvard Med. Sch., Boston, MA; 5FSTRF, Inc., Buffalo, NY; 6NIAID, NIH, Bethesda MD; 7New York Univ. Med. Sch., New York; and 8NICHD, NIH, Bethesda, MD
| ||
| 11:00 115. | Response to Primary Immunization to Tetanus, Diphtheria, H. influenzae Type B and Measles in HIV-Infected Children on HAART A. Pracanica*, P. Russo, C. A. Zaccarelli-Filho, R. Succi, A. Santos, L. Weckx, and M. I. de Moraes-Pinto Fed. Univ. of São Paulo, Brazil
| ||
| 11:15 116. | Association between Mother and Infant Class I and Class II HLA and of Their Concordance with the Risk of Perinatal HIV-1 Transmission A. Polycarpou*1, C. Ntais1, B. T. Korber2, H. A. Elrich3, R. Winchester4, P. Krogstad5, S. Wolinsky6, T. Rostron7, S. L. Rowland-Jones7, A. J. Ammann8, and J. P. A. Ioannidis1 for the Ariel Project 1Univ. of Ioannina, Greece; 2Santa Fe Inst., NM; 3Roche Molecular Systems, Alameda, CA; 4Columbia Univ., New York, NY; 5Univ. of California, Los Angeles; 6Northwestern Univ., Chicago, IL; 7John Radcliffe Hosp., Oxford, UK; and 8Global Strategies for HIV Prevention, San Rafael, CA
| ||
| 11:30 117. | HIV-Specific CD8+ T Cells Are Present at a High Frequency in Breast Milk from HIV-Infected Women S. Sabbaj*, B. Edwards, M. Ghosh, K. Semrau, M. Mulligan, P. Goepfert, and G. Aldrovandi Univ. of Alabama, Birmingham
| ||
| 11:45 118. | CCR5 Genotype and Susceptibility to Transmission of HIV-1 in Women S. Philpott1, B. Weiser1,2, P. Tarwater3, S. Vermund4, C. Kleeberger3, S. Gange3, K. Anastos5, M. Cohen6, R. Greenblatt7, A. Kovacs8, H. Minkoff9, M. Young10, M. Miotti11, M. Dupuis1, C. Chen1, and H. Burger*1 1New York State Dept. of Hlth., Albany; 2Albany Med. Coll., NY; 3Johns Hopkins Univ. Sch. of Hygiene and Publ. Hlth., Baltimore, MD; 4Univ. of Alabama, Birmingham; 5Montefiore Med. Ctr., Bronx, NY; 6Cook County Hosp., Chicago, IL; 7Univ. of California, San Francisco; 8Los Angeles County and Univ. of Southern California Med. Ctr., Los Angeles; 9State Univ. of New York Hlth. Sci. Ctr., Brooklyn; 10Georgetown Univ. Med. Ctr., Washington, DC; and 11NIAID, NIH, Bethesda, MD
| ||
| 12:00 119. | Lack of Effect of HAART on HPV DNA Levels in the Female Genital Tract L. J. Conley1, T. J. Bush1, T. V. Ellerbrock*1, J. Lennox2, F. Wu3, T. Evans-Strickfaden1, C. E. Hart1, and T. C. Wright3 1CDC, Atlanta, GA and 2Emory Univ., Atlanta, GA; and 3Columbia Univ., New York, NY
| ||
| 12:15 120. | Effect of Nevirapine (NVP) for Perinatal HIV Prevention Appears Greatest Among Women with Most Advanced Disease: Subgroup Analyses of HIVNET 012 M. G. Fowler*1, A. Mwatha2, L. Guay3, P. Musoke4, F. Mmiro4, T. Fleming5, and J.B. Jackson3 for the HIVNET 012 Study Team 1CDC, Atlanta, GA; 2Fred Hutchinson Cancer Res. Ctr., Seattle, WA; 3Johns Hopkins Sch. of Med., Baltimore, MD; 4Makerere Univ., Kampala, Uganda; and 5Univ. of Washington, Seattle
|
